Brachytherapy for the treatment of prostate cancer.
Low-dose rate brachytherapy has become a mainstream treatment option for men diagnosed with prostate cancer because of excellent long-term treatment outcomes in low-, intermediate-, and high-risk patients. Largely due to patient lead advocacy for minimally invasive treatment options, high-quality prostate implants have become widely available in the US, Europe, and Japan. The reason that brachytherapy results are reproducible in several different practice settings is because numerous implant quality factors have been defined over the last 20 years, which can be applied objectively to judge the success of the intervention both during and after the procedure. In addition, recent long-term follow-up studies have clarified that the secondary cancer incidence of brachytherapy is not clinically meaningful. In terms of future directions, the study of radiation repair genetics may allow for the counseling physician to better estimate any given patients risk for side effects, thereby substantially reducing the therapeutic uncertainties faced by patients choosing a prostate cancer intervention.
Cesaretti
Jamie A
JA
Department of Radiation Oncology, The Mount Sinai School of Medicine, James J. Peters VA Hospital, New York, NY, USA. jamie.cesaretti@msnyuhealth.org
Stone
Nelson N
NN
Skouteris
Vassilios M
VM
Park
Janelle L
JL
Stock
Richard G
RG
D001918:Brachytherapy / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D009362:Neoplasm Metastasis; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000532:radiotherapy*; D016719:Radioimmunodetection; D012371:Robotics; D015996:Survival Rate
D017430:Prostate-Specific Antigen